Targeting neuroblastoma with advanced alpha particle therapy.
Official title: Image-guided dosimetry-based alpha particle therapy for neuroblastoma.
Funded at Viewpoint Molecular Targeting, INC. · NIH-10677002 · Data updated 2026-11-12
This study is testing a new way to treat neuroblastoma, a common childhood cancer, by using a special therapy that targets cancer cells while trying to keep healthy cells safe, and it's being done in mice that have a similar type of cancer to help make sure it's safe and effective for kids.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Viewpoint Molecular Targeting, INC. NIH-funded |
| Lab location | 1 site (Coralville, UNITED STATES) |
| Project start | August 4, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $961,450 |
| NIH project number | 5R44CA268314-02 |
| Project ID | NIH-10677002 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with neuroblastoma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with neuroblastoma who are not expressing the somatostatin receptor 2 (SSTR2) may not benefit from this targeted therapy.
What this research studies
This research focuses on developing a new treatment for neuroblastoma, the most common pediatric cancer, by using a targeted alpha particle therapy that aims to improve tumor response rates. The approach utilizes a genetically engineered mouse model that closely mimics human neuroblastoma to test the effectiveness and safety of the treatment. By targeting the somatostatin receptor 2 (SSTR2) found in neuroblastoma tumors, the therapy aims to deliver radiation directly to the cancer cells while minimizing damage to healthy tissues. The research will also assess potential side effects, particularly on the kidneys, to ensure patient safety.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for children with neuroblastoma.
How similar studies have gone: Previous research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Viewpoint Molecular Targeting, INC.
Coralville, United States Active
Researchers
- Principal investigator: Schultz, Michael King — Viewpoint Molecular Targeting, INC.
- Study coordinator: Schultz, Michael King
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.